home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2799.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
2KB
|
32 lines
Document 2799
DOCN M94A2799
TI Clinical studies of xenogeneic HIV-1 immunoglobulin.
DT 9412
AU Osther KB; Fralick R; Hung CH; Thorn RM; Verigen Inc., Hopkinton, MA.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):222 (abstract no. PB0318). Unique
Identifier : AIDSLINE ICA10/94369776
AB An intravenously formulated immunoglobulin G (IgG) derived from HIV-1
lysate immunized pigs has been used to treat 16 HIV-1 infected patients
with AIDS signs ranging from asymptomatic to severe. All patients with
AIDS signs have shown improvement for 2 to 3 months in at least one
clinical sign. Placebo controlled, blinded trials are ongoing. Two
patients have received two cycles and one patient three. There has been
no adverse clinical signs associated with retreatment nor have porcine
IgG antibodies developed. In patients with p24 antigen, the treatment
results in immediate and sustained (2-3 mo) clearance. CD4 cell counts
are usually unchanged over a 3-6 month period, although some patients
show increases for 2-3 months. In the 3 cycle treated patient, clinical
signs improved and CD4 counts increased for 2-3 months after each
treatment cycle. The accumulating evidence suggests that this
hyperimmune IgG is tolerated on repeated administration; and that it can
have significant clinical, viral, and immunological effects.
DE Animal Double-Blind Method Human HIV Antibodies/*THERAPEUTIC USE HIV
Core Protein p24/BLOOD HIV Infections/*THERAPY HIV-1/*IMMUNOLOGY
IgG/*THERAPEUTIC USE *Immunization, Passive Leukocyte Count
Swine/IMMUNOLOGY Treatment Outcome T4 Lymphocytes CLINICAL TRIAL
MEETING ABSTRACT RANDOMIZED CONTROLLED TRIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).